Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.440
-0.060 (-4.00%)
At close: Oct 29, 2024, 4:00 PM
1.560
+0.120 (8.33%)
After-hours: Oct 29, 2024, 5:56 PM EDT
Company Description
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Adi George |
Contact Details
Address: Building 7, Kiryat Atidim Tel Aviv, 6158002 Israel | |
| Phone | 972 77 331 0156 |
| Website | chemomab.com |
Stock Details
| Ticker Symbol | CMMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534248 |
| CUSIP Number | 03280X102 |
| ISIN Number | US16385C1045 |
| Employer ID | 81-3676773 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director |
| Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
| Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer and Vice President of Drug Development |
| Barbara Lindheim | Consulting Vice President of Investor and Public Relations, Strategic Communications |
| Jack Lawler | Senior Vice President of Global Clinical Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 11, 2024 | 6-K | Report of foreign issuer |
| Sep 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 12, 2024 | 144 | Filing |
| Sep 9, 2024 | 424B3 | Prospectus |
| Sep 6, 2024 | EFFECT | Notice of Effectiveness |
| Aug 29, 2024 | UPLOAD | Filing |
| Aug 23, 2024 | F-3 | Filing |
| Aug 21, 2024 | 6-K | Report of foreign issuer |
| Aug 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 9, 2024 | D | Notice of Exempt Offering of Securities |